Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 5.4% Today

What is Hims & Hers Health Inc.?

Hims & Hers Health Inc. (NASDAQ: HIMS) is a company focused on telehealth and personalized health and wellness products. The overall market sentiment for HIMS has been bearish today.

Why is Hims & Hers Health Inc. going down?

HIMS stock is down 5.4% on Dec 10, 2025 15:15

• The bearish movement in HIMS stock today could be attributed to the securities fraud class action lawsuit filed against the company. The allegations of deceptive promotion of illegitimate versions of Wegovy, jeopardizing its collaboration with Novo Nordisk, have raised concerns among investors.
• The negative news about the lawsuit may have led to a loss of investor confidence in Hims & Hers Health Inc., resulting in a significant downward pressure on the stock price.
• Investors are likely reacting to the potential risks associated with the allegations, causing a sell-off of HIMS shares as they reassess the company's credibility and future prospects in the telehealth industry.

HIMS Price Chart

HIMS Technical Analysis

HIMS News

(HIMS) Movement as an Input in Quant Signal Sets

This article from Stock Traders Daily discusses Hims & Hers Health Inc. (NASDAQ: HIMS), highlighting strong sentiment across all time horizons supporting an overweight bias. It presents specific AI-generated trading strategies for HIMS, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis also points to an exceptional 112.6:1 risk-reward setup.

https://news.stocktradersdaily.com/news_release/91/HIMS_Movement_as_an_Input_in_Quant_Signal_Sets_120925095802_1765335482.html

HIMS CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds Investors - a Securities Fraud Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. (HIMS)

Kessler Topaz Meltzer & Check, LLP announced that a securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS). The lawsuit alleges that Hims & Hers made materially false or misleading statements and failed to disclose that it was deceptively promoting illegitimate versions of Wegovy, which put patient safety at risk and jeopardized its collaboration with Novo Nordisk. Investors who purchased Hims & Hers securities between April 29, 2025, and June 23, 2025, are encouraged to contact the firm by August 25, 2025, to discuss potentially being appointed as a lead plaintiff.

https://natlawreview.com/press-releases/hims-class-action-filed-kessler-topaz-meltzer-check-llp-reminds-investors

Trending Today

Dash ($DASH) Crypto Forecast: Down 6.5% Today

Hims & Hers Health Inc. Price History

30.09.2025 - HIMS Stock was down 5.2%

• The downward trend in HIMS stock today may be linked to a current securities fraud class action lawsuit against the company, fostering uncertainty and negativity among investors.
• Although HIMS has seen sustained product demand and high platform engagement, a statement issued by Levi & Korsinsky regarding the lawsuit might have exacerbated the stock's decline.
• The minor decrease in HIMS stock price in a bullish market may suggest investor wariness regarding the company's upcoming earnings release and its potential effects on stock performance.
• The evaluation of HIMS against LifeMD in terms of earnings growth and platform size could have also impacted investor confidence, contributing to the bearish movement in HIMS stock.

17.10.2025 - HIMS Stock was down 5.4%

• The rollout of Labs accompanied by yearly plans for comprehensive testing from Hims & Hers Health (NYSE: HIMS) potentially generated optimistic investor attention and sentiment.
• However, the decline in stock price could be linked to competitive activities overshadowing the company's positive disclosures, raising potential investor apprehensions.
• Despite Hims & Hers expanding its technology-driven healthcare model with new services, selling pressure and market dynamics may have contributed to the stock's downward trajectory.
• Investor sentiment towards HIMS appears to be influenced by both company-specific updates and broader market conditions, leading to the observed bearish movement today.

24.09.2025 - HIMS Stock was up 5.3%

• Despite a small price drop, HIMS ended the day on a high note, indicating a strong bullish trend.
• The company's focus on AI-driven personalized healthcare and recent substantial investments likely contributed to increased investor confidence in its growth potential.
• Although not immediately reflected in the stock price, the introduction of a women's health specialty highlights HIMS' dedication to expanding its offerings and customer base.
• With positive initial analyst coverage and favorable comparisons to other value stocks, HIMS appears to be attracting investor attention as a compelling investment opportunity.

05.10.2025 - HIMS Stock was up 5.2%

• Q3 earnings were in line with estimates and revealed a revenue surprise of +2.62%.
• HIMS stock experienced a significant surge post-earnings, potentially influenced by discussions regarding new product offerings on its platform.
• The company's emphasis on expanding AI-driven personalized health and wellness services, coupled with a substantial funding increase, likely influenced the favorable market sentiment.
• Market observations suggest that investors perceive HIMS as a valuable investment compared to other companies in the same sector.

13.10.2025 - HIMS Stock was down 5.5%

• HIMS' ongoing global expansion of AI-driven personalized and subscription-based care, supported by recent funding, indicates a promising growth trajectory.
• Despite these positive developments, market sentiment turned bearish, possibly reflecting concerns regarding the scalability and profitability of new offerings in GLP-1 weight loss, hormone health, and custom treatments.
• Investor caution might stem from doubts about the company's ability to effectively monetize its technology-driven care model in the competitive healthcare sector, contributing to today's bearish stock movement.

11.10.2025 - HIMS Stock was down 5.7%

• HIMS stock took a hit today despite expanding its AI-driven personalized and subscription-based care globally, indicating a disconnect between company growth and market sentiment.
• The decline in third-quarter earnings and contracting margins likely contributed to the bearish movement, overshadowing the positive revenue and subscriber growth.
• The comparison with Omnicell in terms of value may have also influenced investor perception, potentially leading to profit-taking and selling pressure on HIMS stock.
• Overall, the combination of earnings disappointment, margin concerns, and valuation comparisons could have fueled the bearish sentiment surrounding HIMS stock today.

04.10.2025 - HIMS Stock was up 5.2%

• HIMS met Q3 earnings expectations and surpassed revenue forecasts, suggesting a robust financial performance.
• Talks about potentially offering Novo Nordisk's products on its platform were well-received by investors, contributing to an optimistic market response and driving up the stock price.
• Positive investor sentiment was fueled by the company's expansion strategies, introduction of new products, and a significant increase in funding.
• The expectation of sustained product demand and heightened platform engagement prior to the earnings release also played a part in the stock's upward movement.

20.10.2025 - HIMS Stock was down 5.7%

• The stock faced selling pressure, resulting in a decrease in value.
• Despite launching new services such as Labs for comprehensive testing, external factors may have overshadowed positive developments.
• Investor comparisons with other stocks like OMCL could have contributed to the bearish trend.
• Market dynamics and general investor sentiment towards telehealth and wellness firms likely influenced today's decline in the stock price.

21.10.2025 - HIMS Stock was down 6.9%

• The optimism from significant investors towards Hims & Hers Health did not result in a rise in the stock's value, with noticeable selling pressure impacting its performance.
• Despite launching new health testing services through Labs with annual plans, HIMS shares declined, potentially due to external competitive factors influencing investor confidence.
• The market shift may be linked to increased selling activity, signaling a change in market dynamics despite favorable company updates.
• A comparison with another company's stock (OMCL vs. HIMS) implies that investors could be reconsidering their positions in HIMS, contributing to the bearish trend witnessed today.

06.10.2025 - HIMS Stock was down 8.9%

• Third-quarter earnings for HIMS were down compared to the previous year, despite notable growth in revenue and subscribers.
• Investors are currently comparing HIMS to similar companies like Omnicell in the medical information systems sector to evaluate the more attractive investment.
• HIMS met earnings predictions for the third quarter, outperforming revenue expectations. This resulted in a brief stock increase following the earnings disclosure.
• The market reacted negatively to talks about potential associations with Novo Nordisk to provide specific medications through their platform, potentially contributing to the downward trend in the stock.

22.09.2025 - HIMS Stock was down 6.8%

• Despite progress in AI-powered personalized healthcare and the launch of a new women's health specialty, HIMS stock declined, potentially influenced by market sentiment.
• An $870 million investment infusion and positive analyst coverage failed to counterbalance the impact of remarks made by President Trump regarding drug price reductions on HIMS stock.
• Comparing the stock with another for valuation purposes could have influenced investor choices, contributing to the downward movement.
• The bearish trend observed in HIMS stock today appears to be driven by a mix of factors, including external remarks impacting the healthcare industry and investor perceptions regarding the stock's value proposition.

10.11.2025 - HIMS Stock was down 5.4%

• The bearish movement in HIMS stock today could be attributed to the securities fraud class action lawsuit filed against the company. The allegations of deceptive promotion of illegitimate versions of Wegovy, jeopardizing its collaboration with Novo Nordisk, have raised concerns among investors.
• The negative news about the lawsuit may have led to a loss of investor confidence in Hims & Hers Health Inc., resulting in a significant downward pressure on the stock price.
• Investors are likely reacting to the potential risks associated with the allegations, causing a sell-off of HIMS shares as they reassess the company's credibility and future prospects in the telehealth industry.